Patent intelligence · US
US 10851146
Method for preparing liraglutide intermediate polypeptide
Method for preparing liraglutide intermediate polypeptide
Patent details — US 10851146
- Jurisdiction
- US
- Status
- granted
- Grant date
- Dec 1, 2020
- Expiration
- Nov 26, 2040
- Applicant
- AMPHASTAR NANJING PHARMACEUTICALS INC
- Claims
- 12
- CPC classes
- A61K, A61K38/26
Quick answer
US 10851146 (Method for preparing liraglutide intermediate polypeptide) is held by AMPHASTAR NANJING PHARMACEUTICALS INC. Status: granted. Granted Dec 1, 2020. Expires Nov 26, 2040 (14 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- AMPHASTAR NANJING PHARMACEUTICALS INC
- Grant date
- Expiration
- Claims
- 12
- CPC classes
- A61K, A61K38/26
More from AMPHASTAR NANJING PHARMACEUTICALS INC
Related pharmaceutical patents in our USPTO index.
-
US 12383516
Albuterol aerosol suspension formulation for oral inhalation with high amount of green propellant hydrofluoroolefin (HFO) and free of co-solvent
granted -
US 12370241
Nasal powder formulation for treatment of hypoglycemia
granted -
US 12325732
Pro-insulin aspart structure and method for preparing insulin aspart
granted -
US 12226456
Nasal powder formulation for treatment of hypoglycemia
granted -
US 11938089
Medication delivery systems and methods
granted -
US 11524987
Highly purified recombinant human insulin (RHI) API and methods of producing the same
granted -
US 11446360
High-purity inhalable particles of insulin and insulin analogues, and high-efficiency methods of manufacturing the same
granted
Related coverage
Frequently asked questions
What is US patent 10851146?
US 10851146 (Method for preparing liraglutide intermediate polypeptide) is held by AMPHASTAR NANJING PHARMACEUTICALS INC. Status: granted. Granted Dec 1, 2020. Expires Nov 26, 2040 (14 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 10851146?
AMPHASTAR NANJING PHARMACEUTICALS INC is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 15 pharmaceutical patents for this assignee.
When does US 10851146 expire?
Our index shows an expiration date of Nov 26, 2040 (14 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.